[go: up one dir, main page]

WO2000077218A1 - Vaccin contre le virus de la maladie de newcastle - Google Patents

Vaccin contre le virus de la maladie de newcastle Download PDF

Info

Publication number
WO2000077218A1
WO2000077218A1 PCT/IB2000/000748 IB0000748W WO0077218A1 WO 2000077218 A1 WO2000077218 A1 WO 2000077218A1 IB 0000748 W IB0000748 W IB 0000748W WO 0077218 A1 WO0077218 A1 WO 0077218A1
Authority
WO
WIPO (PCT)
Prior art keywords
ndv
virulent
vaccine
dna
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2000/000748
Other languages
English (en)
Inventor
Austen Shawn Cohen
Gerrit Johannes Viljoen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agricultural Research Council
Original Assignee
Agricultural Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agricultural Research Council filed Critical Agricultural Research Council
Priority to AU46060/00A priority Critical patent/AU4606000A/en
Publication of WO2000077218A1 publication Critical patent/WO2000077218A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • This invention relates to a circular polynudeotide vaccine, capable of expressing a fusion (F) protein of a virulent strain of Newcastle disease virus (NDV).
  • This invention further relates to recombinant DNA and a gene encoding such F protein, and bioprecursors and products thereof.
  • a known DNA based vaccine is described in: PROTECTION OF CHICKENS FROM NEWCASTLE DISEASE BY VACCINATION WITH A LINEAR PLASMA DNA EXPRESSING THE F PROTEIN OF NEWCASTLE DISEASE VIRUS; Masashi Sakaguchi, Hideki Nakamura, Kengo Sonoda, Fukusaburo Hamada and Kanji Hirai, Vaccine, Volume 14, Number 8, pp 747 - 752, 1996.
  • a plasmid DNA vaccine comprising plasmid DNA expressing the F protein of an avirulent strain of Newcastle disease virus (NDV- F). Birds were infected with either circular or linearised plasmid DNA. The article concludes that birds injected with circular plasmid DNA did not produce a significant level of antibody against NDV-F, however, two of five birds injected with the linearised plasmid DNA produced high levels of the antibody.
  • a vaccine including a recombinant plasmid nucleic acid sequence, or part thereof, coding for the F protein of a virulent strain of Newcastle disease virus (NDV), or a portion or bioprecursor thereof.
  • NDV Newcastle disease virus
  • the recombinant nucleic acid sequence may comprise plasmid DNA.
  • the recombinant DNA may include plasmid vector DNA and DNA foreign thereto, the foreign DNA coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV.
  • the foreign DNA may have a nucleic acid sequence substantially as depicted in annexure A or part thereof.
  • the foreign DNA further may include at least one other gene coding for other proteins or compositions.
  • Said other gene may be selected from the group comprising HN gene, type 1 interferon gene, and interferon -gamma gene.
  • a gene, or part thereof coding for the F protein of a virulent strain of NDV is provided.
  • the gene may have a nucleic acid sequence substantially as depicted in annexure A.
  • recombinant DNA comprising a plasmid vector DNA and DNA foreign thereto, the foreign DNA coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV.
  • a DNA molecule having the following terminal sequences: 5':TGGATCCGGT GATGACCAAA GG: 3'.
  • the above DNA molecule may have in the order of 1500 to 2000 base pairs.
  • a genetic vaccine comprising a recombinant DNA molecule including a DNA sequence coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV.
  • a recombinant subunit vaccine capable of expressing an F protein of a virulent strain of NDV via a suitable expression system.
  • the invention further relates to the expression of such a recombinant subunit vaccine via any suitable prokaryotic or eukaryotic expression system such as viral-vectored-; yeast-; plant-; mammalian-; fish-; or bacterial expression systems.
  • a suitable prokaryotic or eukaryotic expression system such as viral-vectored-; yeast-; plant-; mammalian-; fish-; or bacterial expression systems.
  • a vaccine comprising a peptide derived from a cloned ssRNA gene coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV.
  • the invention further relates to F protein of a virulent strain of NDV produced by the method described above.
  • the invention further relates to F protein of a virulent strain of NDV as described above as a reagent for use in an assay method for detecting virulent NDV infections.
  • the invention further relates to the use of F protein of a virulent strain of NDV as described above as a vaccine component for eliciting a protective effect in animals against virulent NDV.
  • a diagnostic serotype sequence specific probe derived from a cloned ssRNA gene coding for a polypeptide bioprecursor of the F glycoprotein of a virulent strain of NDV.
  • the invention further relates to the use of a serotype sequence specific probe as described above in a method of diagnosing virulent NDV in animals.
  • the invention further relates to the use of sequence specific ssDNA oligonucleotides or primers in an amplification based method diagnosing the presence of a virulent NDV in animals.
  • This aspect of the invention may also be applied to differential diagnosis of virulent and non-virulent (or vaccine) virus presence or infection.
  • a method of treatment of virulent NDV including the step of administering to an animal, an effective amount of a vaccine, a genetic vaccine or a recombinant subunit vaccine as hereinbefore described.
  • the vaccine is administered by intra-muscular injection; intra- dermal injection; sub-cutaneous injection; oral immunisation; occular immunisation; in ovo immunisation; and/or by bacterial vector delivery.
  • a strain (Onderstepoort vaccine strain) of the Newcastle disease virus was obtained in 1985 from the Onderstepoort Vaccine Factory (now Onderstepoort Biological Products).
  • RNA Extraction 30ml of infective allantoic fluid was centrifuged at 2000g for 5 min. Supernatant was then centrifuged at 88000g for 1 hour and the virus pellet suspended in 1 ml TNE (1 OmM Tris pH7.4, 10OmM NaCI, 1 mM Na 2 EDTA).
  • cDNA was prepared by incubating 3 ⁇ l RNA, 1.4 ⁇ l 5X RT buffer (Superscript,
  • the tube was then incubated at 37°C for 1hr.
  • reaction was then carried out using a denaturing temperature of 94°C for 30 sec, annealing at 38°C for 1 min and elongation at 72°C for 5 min for 30 cycles.
  • An amplicon obtained using the RT-PCR method described above was selected for cloning into the commercially available pCR-Blunt vector system (Invitrogen). A protocol outlined in the kit was followed in order to obtain potential clones.
  • sequencing of the insert terminal ends was performed using M13 Forward (-40) and Reverse primers. Sequencing was carried out using the standard di-deoxy method developed by Sanger et al. (Sanger F., Nicklen S. and Coulson A.R., 1977, DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. U.S.A. 74:5463-5467).
  • Vaccines for example: DNA vaccines, recombinant vaccines, subunit vaccines and edible vaccines; and
  • RNA/DNA probing for example: RNA/DNA probing, Elisa and PCR.
  • the DNA sequence may be used in conjunction with one or more other genes, coding for other proteins or compositions, such as the HN gene, type 1 interferon gene, and interferon -gamma gene.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne un vaccin de polynucléotide circulaire, capable d'exprimer une protéine de fusion (F) d'une souche virulente du virus de la maladie de Newcastle (NDV). Elle se rapporte aussi à l'ADN recombinant, à un gène codant pour une telle protéine F, ainsi qu'à des bioprécurseurs et des produits associés. Le gène peut être utilisé en conjonction avec un ou plusieurs autres gènes, qui codent pour d'autres protéines ou d'autres compositions, tels que le gène de HN, le gène de l'interféron de type 1, et le gène de l'interféron - gamma.
PCT/IB2000/000748 1999-06-10 2000-06-05 Vaccin contre le virus de la maladie de newcastle Ceased WO2000077218A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU46060/00A AU4606000A (en) 1999-06-10 2000-06-05 Vaccine for newcastle disease virus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA99/3896 1999-06-10
ZA993896 1999-06-10

Publications (1)

Publication Number Publication Date
WO2000077218A1 true WO2000077218A1 (fr) 2000-12-21

Family

ID=25587769

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/000748 Ceased WO2000077218A1 (fr) 1999-06-10 2000-06-05 Vaccin contre le virus de la maladie de newcastle

Country Status (2)

Country Link
AU (1) AU4606000A (fr)
WO (1) WO2000077218A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100454870B1 (ko) * 2001-07-30 2004-11-03 주식회사 인트론바이오테크놀로지 뉴캐슬병 바이러스의 ｆ 단백질과 ｈｎ 단백질 및 그의유전자들
CN1293195C (zh) * 2005-09-02 2007-01-03 中国农业科学院哈尔滨兽医研究所 新城疫LaSota疫苗株反向遗传操作系统及其应用
CN102716478A (zh) * 2012-06-26 2012-10-10 普莱柯生物工程股份有限公司 新、支二联灭活疫苗及其制备方法
US8377450B2 (en) 2009-11-30 2013-02-19 United Cancer Research Institute Clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114774373B (zh) * 2022-04-27 2024-07-05 北京市农林科学院 信鸽新城疫病毒基因工程改造弱毒株及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0227414A2 (fr) * 1985-12-18 1987-07-01 Btg International Limited Clones de gènes du virus de la maladie de Newcastle
EP0252060A1 (fr) * 1986-06-30 1988-01-07 Smithkline Beckman - Animal Health Products Séquence d'ADN, molécules d'ADN recombinantes et procédé pour la production de la protéine de fusion du virus de la maladie de Newcastle ou de polypeptides équivalents, produits obtenus et préparation les contenant
WO1996012808A1 (fr) * 1994-10-20 1996-05-02 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Preparation d'acide nucleique pour l'immunisation et procede d'immunisation au moyen de ladite preparation
FR2751225A1 (fr) * 1996-07-19 1998-01-23 Rhone Merieux Formule de vaccin polynucleotidique aviaire

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0227414A2 (fr) * 1985-12-18 1987-07-01 Btg International Limited Clones de gènes du virus de la maladie de Newcastle
EP0252060A1 (fr) * 1986-06-30 1988-01-07 Smithkline Beckman - Animal Health Products Séquence d'ADN, molécules d'ADN recombinantes et procédé pour la production de la protéine de fusion du virus de la maladie de Newcastle ou de polypeptides équivalents, produits obtenus et préparation les contenant
WO1996012808A1 (fr) * 1994-10-20 1996-05-02 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Preparation d'acide nucleique pour l'immunisation et procede d'immunisation au moyen de ladite preparation
FR2751225A1 (fr) * 1996-07-19 1998-01-23 Rhone Merieux Formule de vaccin polynucleotidique aviaire

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KANT, A. ET AL.: "Differentiation of virulent and non-virulent strains of Newcastle disease virus within 24 hours by polymerase chain reaction", AVIAN PATHOLOGY, vol. 26, December 1997 (1997-12-01), pages 837 - 849, XP000960911 *
NAOHIRO, K. ET AL.: "Protective effect of individual glycoproteins of Newcastle disease virus expressed in insect cells: The fusion protein derived from an avirulent strain had lower protective efficacy.", VIRUS RESEARCH, vol. 32, 1994, pages 373 - 379, XP000960765 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100454870B1 (ko) * 2001-07-30 2004-11-03 주식회사 인트론바이오테크놀로지 뉴캐슬병 바이러스의 ｆ 단백질과 ｈｎ 단백질 및 그의유전자들
CN1293195C (zh) * 2005-09-02 2007-01-03 中国农业科学院哈尔滨兽医研究所 新城疫LaSota疫苗株反向遗传操作系统及其应用
US8377450B2 (en) 2009-11-30 2013-02-19 United Cancer Research Institute Clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
CN102716478A (zh) * 2012-06-26 2012-10-10 普莱柯生物工程股份有限公司 新、支二联灭活疫苗及其制备方法

Also Published As

Publication number Publication date
AU4606000A (en) 2001-01-02

Similar Documents

Publication Publication Date Title
US20240100151A1 (en) Variant strain-based coronavirus vaccines
JP2534246B2 (ja) ニユ−カツスル病ウイルス遺伝子クロ−ン
Lopez et al. The L protein of Rift Valley fever virus can rescue viral ribonucleoproteins and transcribe synthetic genome-like RNA molecules
EP0490972B2 (fr) Vaccins et systemes d'expression de virus arn recombinant a brin negatif
Kraatz et al. Deletion mutants of Schmallenberg virus are avirulent and protect from virus challenge
US8647637B2 (en) Immunogenic compositions, vaccines and diagnostics based on canine distemper viruses circulating in north american dogs
ES2588225T3 (es) Secuencias de ácido nucleico de un virus de pece y el uso de las mismas
JP2010259445A (ja) 弱毒化ペスチウイルス
KR19990022335A (ko) 인플루엔자의 신규한 재조합 감온성 돌연변이체
Vennema et al. Genomic organization and expression of the 3′ end of the canine and feline enteric coronaviruses
JP2009529861A (ja) 鳥インフルエンザウイルスのｈ５ヘマグルチニンを発現する組み換えニューキャッスル病ウイルス
CN112063592A (zh) 非洲猪瘟多基因联合缺失减毒株的构建及作为疫苗的应用
CN101563361A (zh) 能够感染犬科动物的流感病毒及其用途
CN113293145A (zh) 一种麻疹病毒活载体新冠疫苗
de Swart et al. Advantages and challenges of Newcastle disease virus as a vector for respiratory mucosal vaccines
US6231863B1 (en) DNA sequences, molecules, vectors and vaccines for feline calicivirus disease and methods for producing and using same
US20230029979A1 (en) Broadly protective bovine parainfluenza 3 virus and bovine viral diarrhea virus vaccine
EP3894429B1 (fr) Particules de réplicon du virus de la fièvre hémorragique de crimée-congo et utilisation correspondante
US20100028384A1 (en) Yeast expressed classical swine fever virus glycoprotein e2 and use thereof
JP4691495B2 (ja) コロナウイルススパイクｓ１融合蛋白及びその発現ベクター
WO2000077218A1 (fr) Vaccin contre le virus de la maladie de newcastle
Ling et al. Sequence and in vitro expression of the phosphoprotein gene of avian pneumovirus
TW202309290A (zh) 去優化之sars-cov-2變體及其方法及用途
US20240226258A1 (en) In-vitro transcript mrna and pharmaceutical composition comprising same
Kanno et al. The complete nucleotide sequence of the PanAsia strain of foot-and-mouth disease virus isolated in Japan

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 200109150

Country of ref document: ZA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP